ArticlePharmaceuticals (Basel, Switzerland)2025
Establishing Multi-Dimensional LC-MS Systems for Versatile Workflows to Analyze Therapeutic Antibodies at Different Molecular Levels in Routine Operations.
Katrin Heinrich, Sina Hoelterhoff, Saban Oezipek, Martin Winter, Tobias Rainer, Lucas Hourtoulle, Ingrid Grunert, Tobias Graf, Michael Leiss, Anja Bathke
Abstract read
In one paragraphArticle in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Katrin HeinrichPharma Technical Development, Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.ORCID 0000-0001-5256-9950 Sina HoelterhoffPharma Technical Development, F. Hoffmann-La Roche, Grenzacherstrasse 124, 4070 Basel, Switzerland.ORCID 0000-0003-2935-8279 Saban OezipekPharma Technical Development, F. Hoffmann-La Roche, Grenzacherstrasse 124, 4070 Basel, Switzerland.ORCID 0000-0001-5147-0983 Martin WinterPharma Technical Development, Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.ORCID 0009-0003-2855-3627 Tobias RainerPharma Technical Development, Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.ORCID 0000-0002-3918-4084 Lucas HourtoullePharma Technical Development, F. Hoffmann-La Roche, Grenzacherstrasse 124, 4070 Basel, Switzerland.
Ingrid GrunertPharma Technical Development, Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.ORCID 0000-0002-5596-1015 Tobias GrafPharma Technical Development, Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.ORCID 0000-0002-0275-7352 Michael LeissPharma Technical Development, Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.
Anja BathkePharma Technical Development, F. Hoffmann-La Roche, Grenzacherstrasse 124, 4070 Basel, Switzerland.ORCID 0000-0002-8823-4578 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
HPLC method characterizationimmobilized enzyme reactor (IMER)ion exchange chromatography (IEC)method optimizationmulti-dimensional liquid chromatography coupled to mass spectrometry (mD-LC-MS(/MS))post-translational modifications (PTMs)therapeutic antibody(ultra) high-performance liquid chromatography ((U)HPLC)
Identifiers
PMID40143177
PMCPMC11944941
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390